免疫检查点阻断通过扩增效应 CD8⁺ T 细胞克隆增强淋巴细胞清除性化疗诱导的抗肿瘤免疫
Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Invasive Melanoma Arising in a BAP1-Inactivated Melanocytic Tumor With NRAS Mutation: A Report of Exceptional Case With Emphasis on Its Genomic Features and Review of the Literature.
Invasive Melanoma Arising in a BAP1-Inactivated Melanocytic Tumor With NRAS Mutation: A Report of Exceptional Case With Emphasis on Its Genomic Features and Review of the Literature.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
BAP1失活黑色素细胞肿瘤是一种独特的实体,表现为BAP1蛋白缺失和上皮样形态。它与Spitz痣和痣样黑色素瘤有组织病理学特征重叠,可散发或与种系BAP1易感综合征相关。这些病变通常有TIL(肿瘤浸润淋巴细胞)和罕见的核分裂象。它们通常呈惰性,但黑色素瘤可在种系和散发病例中发生。大多数显示BRAF V600E和BAP1突变。
我们描述了一名诊断为BAP1肿瘤易感综合征(BAP1-TPDS)的患者中的四个肿瘤:两个在BIMT中发生的侵袭性黑色素瘤和两个恶性潜能不确定的BIMT。分子分析和荧光原位杂交(FISH)显示黑色素瘤和BAP1失活黑色素细胞肿瘤成分中存在BAP1和NRAS突变,仅在黑色素瘤成分中获得6p25(RREB1)。患者完成了pembrolizumab辅助治疗,无转移证据。这是一例罕见的BIMT表现,伴有BAP1和NRAS突变,无BRAF V600突变,且所有病变细胞中BAP1免疫反应性缺失。
我们的病例增进了对BAP1失活黑色素细胞肿瘤组织形态学和突变谱的理解。
BAP1-inactivated melanocytic tumor is a distinct entity with loss of BAP1 protein and epithelioid morphology. It shares histopathologic features with Spitz nevus and nevoid melanoma, and it can occur sporadically or with germline BAP1 predisposition syndrome. These lesions typically have tumor-infiltrating lymphocytes and infrequent mitoses. They are generally indolent, though melanoma can arise in both germline and sporadic cases. Most show BRAF V600E and BAP1 mutations.
We describe four tumors in one patient diagnosed with BAP1-tumor predisposition syndrome (BAP1-TPDS): two invasive melanomas arising in BIMT and two BIMTs with uncertain malignant potential. Molecular analysis and fluorescence in situ hybridization (FISH) revealed BAP1 and NRAS mutations in melanoma and BAP1-inactivated melanocytic tumor components, with a gain of 6p25 (RREB1) in the melanoma component only.
The patient completed pembrolizumab adjuvant therapy with no evidence of metastasis. This is a rare presentation of BIMT with BAP1 and NRAS mutations, absence of BRAF V600 mutation, and loss of BAP1 immunoreactivity in all lesional cells.
Our case adds to the understanding of the histomorphologic and mutational spectrum in BAP1-inactivated melanocytic tumors.
MEMBER ACCOUNT
登录成功会直接打开下一页。